Technology | Magnetic Resonance Imaging (MRI) | January 24, 2019

First quantitative AI tool for biliary disease enables quantitative and objective assessment of the bile ducts for the first time

FDA Clears Perspectum's MRCP+ Digital Biliary Tree Viewer

January 24, 2019 — Perspectum Diagnostics received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its MRCP+ advanced biliary visualization software.

Perspectum has developed quantitative magnetic resonance imaging (MRI) and artificial intelligence (AI) algorithms for magnetic resonance cholangiopancreatography (MRCP) images to provide improved visualization of intra-hepatic ducts, and measure the widths of bile ducts, biliary tree volume and gallbladder volume. Combining image viewing, processing and reporting tools, the metrics provided are designed to support physicians in the visualization, evaluation, monitoring and reporting of hepatobiliary structures. This is especially relevant for serial evaluation in primary sclerosing cholangitis (PSC) patients.

"I am excited by the FDA clearance of MRCP+. Non-invasive MRCP+ detection of both the numbers and diameters of strictures in patients with PSC has the potential to become a primary end point for therapeutic trials in PSC, a disease for which no effective treatments exist,” commented John M Vierling, professor of medicine and surgery, Baylor College of Medicine and former president of the American Association for the Study of Liver Diseases.

The diagnosis of PSC is hindered by lack of effective biomarkers. Interpretation of conventional MRCPs itself is both qualitative and subject to relatively low inter-operator reliability. Perspectum worked closely with patients with biliary disease to design and validate the software, scanning over 140 patients. MRCP+ has shown diagnostic potential for PSC in a study released at AASLD The Liver Meeting 2018 and is being evaluated for acute biliary imaging later this year.

Martine Walmsley, chair of trustees for the organization PSC Support, said, "The ability to diagnose and monitor the progression of PSC is needed to help develop new treatments, improve methods for cancer surveillance, and allow the early management of symptoms and complications of PSC. To this end we welcome the clearance of MRCP+ which will provide additional information for clinicians and researchers, helping address unmet need for patients with PSC."

MRCP+ is already cleared for clinical use in Europe, with CE-marking. It can process data from all 1.5T and 3T GE, Siemens and Philips MR scanners that support 3-D MRCP sequences, providing standardized quantitative metrics for the pancreatobiliary system. MRCP+ is safe, non-invasive, involves no contrast and a typical scan takes less than 15 minutes with same-day results.

For more information: www.perspectum-diagnostics.com


Related Content

News | Bone Densitometry Systems

June 19, 2025 — Naitive Technologies has published results demonstrating the diagnostic performance of its AI-powered ...

Time June 18, 2025
arrow
News | Lung Imaging

June 18, 2025 — Exo recently announced that now included on its Exo Iris is the first ever FDA 510(k) cleared AI for ...

Time June 18, 2025
arrow
News | Digital Pathology

June 11, 2025 — Diagnostic laboratory leaders view digital pathology and artificial intelligence (AI) as pivotal to ...

Time June 12, 2025
arrow
News | Lung Imaging

June 11, 2025 — To prepare healthcare workforces and providers for an AI-driven future, Qure.ai has expanded its Global ...

Time June 11, 2025
arrow
News | Radiology Imaging

June 10, 2025 — CIVIE has announced the official launch of RadPod, an AI-driven, on-demand radiology platform designed ...

Time June 10, 2025
arrow
News | Ultrasound Imaging

June 4, 2025 — RadNet, Inc., a provider of high-quality, cost-effective diagnostic imaging services and digital health ...

Time June 09, 2025
arrow
News | Mammography

June 9, 2025 — A new independent, peer-reviewed study published in the journal Clinical Breast Cancer reinforces the ...

Time June 09, 2025
arrow
News | Imaging Software Development

June 05, 2025 — Nano-X Imaging Ltd. has announced that its deep-learning medical imaging analytics subsidiary, Nanox AI ...

Time June 05, 2025
arrow
News | Prostate Cancer

June 5, 2025 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time June 05, 2025
arrow
News | Ultrasound Imaging

June 3, 2025 — In a collaborative study between the Departments of Radiology at the Children’s Hospital of Philadelphia ...

Time June 04, 2025
arrow
Subscribe Now